Porcine Adenovirus-Based Viral Vectors for Swine Vaccines: A Scoping Review and Future Perspectives
Authors:
- Nattawooti SthitmateeNattawooti Sthitmatee
- Karnrawee SuanpatKSKarnrawee Suanpat
- Yupa SingtonYSYupa Sington
- Anucha MuenthaisongAMAnucha Muenthaisong
- Kanokwan SangkakamKSKanokwan Sangkakam
- Boondarika NamboopphaBNBoondarika Nambooppha
- Amarin RittipornlertrakARAmarin Rittipornlertrak
- Nisachon ApindaNANisachon Apinda
- Pongpisid KoonyosyingPKPongpisid Koonyosying
- Thanya VarinrakTVThanya Varinrak
- Khwanchai KreausukonKKKhwanchai Kreausukon
Open Access
Abstract
Porcine adenoviruses (PAdVs) are promising but still underdeveloped viral-vector platforms for swine vaccine development. Compared with human adenovirus-based vectors, PAdV vectors may offer potential advantages in host association, veterinary relevance, and mucosal delivery while avoiding direct reliance on common human adenovirus backbones. This review summarizes current knowledge on PAdV biology, vector engineering, vaccine applications, immune responses, translational challenges, and future priorities. Early studies showed that recombinant PAdV vectors can express heterologous antigens from important swine pathogens, including classical swine fever virus, pseudorabies virus, and transmissible gastroenteritis virus. The strongest direct proof-of-concept evidence comes from recombinant PAdV expressing classical swine fever virus E2/gp55, which induced neutralizing antibodies and protection in pigs. Comparative adenovirus-vectored swine vaccine studies support the broader feasibility of adenoviral antigen delivery for porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, swine influenza, and African swine fever, but these data should not be interpreted as direct validation of PAdV for these diseases. Major gaps remain in anti-PAdV immunity, genetic stability, biosafety, shedding, target-animal safety, DIVA compatibility, manufacturing, and regulatory readiness. Recent advances in PAdV-5 reverse genetics provide new opportunities for modern vector design.Keywords
Funding Information
- Chiang Mai University (214459)
- Thailand Science Research and Innovation (69A104000003)
This publication has 77 references indexed in Scilit:
- Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needsBiotechnology and Bioengineering, 2021
- Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccineArchives of Virology, 2020
- Improved virus purification processes for vaccines and gene therapyBiotechnology and Bioengineering, 2015
- Immune responses in pigs induced by recombinant canine adenovirus 2 expressing the glycoprotein 5 of porcine reproductive and respiratory syndrome virusVeterinary Research Communications, 2010
- Novel marker vaccines against classical swine feverVaccine, 2007
- Development of nonhuman adenoviruses as vaccine vectorsVaccine, 2006
- Porcine adenovirus as a delivery system for swine vaccines and immunotherapeuticsThe Veterinary Journal, 2005
- Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virusVaccine, 2004
- Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 geneArchives of Virology, 2001
- Nucleotide Sequence and Transcription Map of Porcine Adenovirus Type 3Virology, 1998